Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

Manon Buijs; Josephina A. Vossen; Jean Francois H. Geschwind; Takayoshi Ishimori; James M. Engles; Obele Acha-Ngwodo; Richard L. Wahl; Mustafa Vali

doi:10.1007/s10637-008-9145-0

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

Manon Buijs, Josephina A. Vossen, Jean Francois H. Geschwind, Takayoshi Ishimori, James M. Engles, Obele Acha-Ngwodo, Richard L. Wahl, Mustafa Vali

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p=0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

Original language	English
Pages (from-to)	120-123
Number of pages	4
Journal	Investigational New Drugs
Volume	27
Issue number	2
DOIs	https://doi.org/10.1007/s10637-008-9145-0
State	Published - Apr 2009

Keywords

3-Bromopyruvate
Animal model
Breast cancer
FDG
RMT

Access to Document

10.1007/s10637-008-9145-0

Cite this

@article{5a381b549a514c9ab3e41a78bfb6468a,

title = "Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer",

abstract = "To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p=0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.",

keywords = "3-Bromopyruvate, Animal model, Breast cancer, FDG, RMT",

author = "Manon Buijs and Vossen, {Josephina A.} and Geschwind, {Jean Francois H.} and Takayoshi Ishimori and Engles, {James M.} and Obele Acha-Ngwodo and Wahl, {Richard L.} and Mustafa Vali",

year = "2009",

month = apr,

doi = "10.1007/s10637-008-9145-0",

language = "English",

volume = "27",

pages = "120--123",

journal = "Investigational New Drugs",

issn = "0167-6997",

number = "2",

}

TY - JOUR

T1 - Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

AU - Buijs, Manon

AU - Vossen, Josephina A.

AU - Geschwind, Jean Francois H.

AU - Ishimori, Takayoshi

AU - Engles, James M.

AU - Acha-Ngwodo, Obele

AU - Wahl, Richard L.

AU - Vali, Mustafa

PY - 2009/4

Y1 - 2009/4

N2 - To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p=0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

AB - To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. Materials and Methods: Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later. Results: 3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p=0.002). FDG uptake did not significantly decrease in normal tissues after treatment. Conclusion: Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.

KW - 3-Bromopyruvate

KW - Animal model

KW - Breast cancer

KW - FDG

KW - RMT

UR - http://www.scopus.com/inward/record.url?scp=66949147345&partnerID=8YFLogxK

U2 - 10.1007/s10637-008-9145-0

DO - 10.1007/s10637-008-9145-0

M3 - Article

C2 - 18553054

AN - SCOPUS:66949147345

SN - 0167-6997

VL - 27

SP - 120

EP - 123

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 2

ER -

Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this